Gulick RM, Mellors JW, Havlir D.
et al. Treatment with indinavir, zidovudine, and lamivudine in adults with
human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med.1997;337:734-739.
Montaner JSG, Reiss P, Cooper D.
et al. A randomized, double-blind trial comparing combinations of nevirapine,
didanosine, and zidovudine for HIV-infected patients: the INCAS trial. JAMA.1998;279:930-937.
Carpenter CCJ, Fischl MA, Hammer SM.
et al. Antiretroviral therapy for HIV infection in 1997: updated recommendations
of the International AIDS Society–USA Panel. JAMA.1997;277:1962-1969.
Department of Health and Human Services and Henry J Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults
and adolescents. MMWR Morb Mortal Wkly Rep.1998; 47(RR-05):43-82.
Deeks S, Loftus R, Cohen P, Chin S, Grant R. Incidence and predictors of virologic failure to indinavir or/and ritonavir
in an urban health clinic. Paper presented at: 37th Interscience Conference on Antimicrobial
Agents and Chemotherapy; September 28, 1997; Toronto, Ontario. Abstract LB-2.
Haubrich R, Currier J, Forthal D.
et al. Low rate of maximal suppression of HIV-1 RNA in a trial of RNA monitoring
in clinical practice. Paper presented at: 37th Interscience Conference on Antimicrobial
Agents and Chemotherapy; September 28, 1997; Toronto, Ontario. Abstract I-128b.
Salit IE, Waring V. Protease inhibitors: use and effects in an HIV clinic. Paper presented at: 37th Interscience Conference on Antimicrobial
Agents and Chemotherapy; September 28, 1997; Toronto, Ontario. Abstract I-99.
Rozenbaum W, Adda N, Wirbel E, Hadacek B, Schneider B, Costagliola D. Predictors and incidence of failure in 500 advanced stage HIV patients
treated with indinavir. Paper presented at: Fifth Conference on Retroviruses and Opportunistic
Infections; February 3, 1998; Chicago, Ill. Abstract 420.
Condra JH, Holder DJ, Schleif WA.
et al. Genetic correlates of in vivo viral resistance to indinavir, a human
immunodeficiency virus type 1 protease inhibitor. J Virol.1996;70:8270-8276.
Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine isolated during prolonged
Larder BA, Kemp SD. Multiple mutations in HIV-1 reverse transcriptase confers high-level
resistance to zidovudine. Science.1989;246:1155-1158.
Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant
to 3‘-thiacytidine inhibitors due to a mutation in the YMDD region of
reverse transcriptase. Proc Natl Acad Sci U S A.1993;90:5653-5656.
Schinazi RF, Lloyd Jr RM, Nguyen MH.
et al. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine
nucleosides. Antimicrob Agents Chemother.1993;37:875-881.
Gao Q, Gu Z, Parniak MA.
et al. The same mutation that encodes low-level human immunodeficiency virus
type 1 resistance to 2‘,3‘-dideoxyinosine and 2‘,3‘-dideoxycytidine
confers high-level resistance to the (-) enantiomer of 2‘,3‘-dideoxy-3‘-thiacytidine. Antimicrob Agents Chemother.1993;37:1390-1392.
Gunthard HF, Wong JK, Ignacio CC.
et al. Human immunodeficiency virus replication and genotypic resistance in
blood and lymph nodes after a year of potent antiretroviral therapy. J Virol.1998;72:2422-2428.
Kempf DJ, Rode RA, Xu Y.
et al. The duration of viral suppression during protease inhibitor therapy
for HIV-1 infection is predicted by plasma HIV-1 RNA at the nadir. AIDS.1998;12:F9-F14.
Schuurman R, Nijhuis M, van Leeuwen R.
et al. Rapid changes in human immunodeficiency virus type 1 RNA load and appearance
of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis.1995;171:1411-1419.
Kuritzkes DR, Quinn JB, Benoit SL.
et al. Drug resistance and virologic response in NUCA 3001, a randomized trial
of lamivudine (3TC) versus zidovudine (ZDV) versus ZDV plus 3TC in previously
untreated patients. AIDS.1996;10:975-981.
Danner SA, Carr A, Leonard JM.
et al. A short-term study of the safety, pharmacokinetics, and efficacy of
ritonavir, an inhibitor of HIV-1 protease. N Engl J Med.1995;333:1528-1533.
Markowitz M, Saag M, Powderly WG.
et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to
treat HIV-1 infection. N Engl J Med.1995;333:1534-1539.
Connick E, Lederman M, Kotzin B.
et al. Immunologic effects of 48 weeks of AZT/3TC/ritonavir. Paper presented at: Fifth Conference on Retroviruses and Opportunistic
Infections; February 5, 1998; Chicago, Ill. Abstract LB-14.
Autran B, Carcelain G, Li TS.
et al. Positive effects of combined antiretroviral therapy on CD4+
T cell homeostasis and function in advanced HIV disease. Science.1997;277:112-116.
Buckton KE, Brown WM, Smith PG. Lymphocyte survival in men treated with x-rays for ankylosing spondylitis. Nature.1967;214:470-473.
Michie CA, McLean A, Alcock C, Beverley PC. Lifespan of human lymphocyte subsets defined by CD45 isoforms. Nature.1992;360:264-265.
Mackall CL, Fleisher TA, Brown MR.
et al. Distinctions between CD8+ and CD4+ T-cell regenerative
pathways result in prolonged T-cell subset imbalance after intensive chemotherapy. Blood.1997;89:3700-3707.
Hammer SM, Squires KE, Hughes MD.
et al. A controlled trial of two nucleoside analogues plus indinavir in persons
with human immunodeficiency virus infection and CD4 cell counts of 200 per
cubic millimeter or less. N Engl J Med.1997;337:725-733.
Hirsch M, Meibohm A, Rawlins S, Leavitt R.for the Protocol 039 (Indinavir) Study Group. Indinavir in combination with ZDV and 3TC in ZDV-experienced patients
with CD4 cell count ≤ 50 cells/mm3– 60 week follow-up. Paper presented at: Fifth Conference on Retroviruses and Opportunistic
Infections; February 3, 1998; Chicago, Ill. Abstract 383.
Wong JK, Hezareh M, Gunthard HF.
et al. Recovery of replication-competent HIV despite prolonged suppression
of plasma viremia. Science.1997;278:1291-1295.
Finzi D, Hermankova M, Pierson T.
et al. Identification of a reservoir for HIV-1 in patients on highly active
antiretroviral therapy. Science.1997;278:1295-1300.
Chun TW, Stuyver L, Mizell SB.
et al. Presence of an inducible HIV-1 latent reservoir during highly active
antiretroviral therapy. Proc Natl Acad Sci U S A.1997;94:13193-13197.